dividends

yesterday I posted about the possibility of future dividends being paid to ADO shareholders. today I'm more than comfortable to add my reasoning.

before I start, this is not financial advice, just my opinion. I have had several posters start to follow me and others generously liking some of my posts. I want to remind all that I rode this baby all the way up to the previous 28c high and all the way down again. sold a few a long the way but my track record isn't stellar!!! so DYOR.....

to add to the above I did start a thread a few weeks ago about Anteotech becoming a manufacture, so similar to a broken clock being correct a couple of times a day, sometimes it works out.

firstly our covid ART test. we have confirmed manufacturing capability of 8m complete tests and an extra 24m test strips. these tests give extremely high margins to companies bottom lines. this volume alone, all sold could result in dividends

but this isn't the end of our manufacturing ambitions. Operon's manufacturing will triple in the next couple of years and we have this from Derek
"Our initial investment in Brisbane will increase that capacity by an estimated 12 million lateral flow strips per year. We will increase this capability as required as EuGeni test demand across the entire range of tests we produce grows.”
another $4m and we could add another 12m test strip capacity = 44m. another $4m and we add another 12m strip capacity= 56m. I'll stop there.

we have our point of difference, our exceptionally sensitive covid art saliva test currently trialling in the UK. results could be released in a week or weeks. the one we changed from India to the UK. and with the UK TPP program having very similar test requirements to those we produced in our VIDRL trial. hmmmm, thanks Dal11 (read some of those posts for a reminder)

we are expanding our accreditations with MDSAP to help with the submission of a range of tests to the TGA, FDA and IVDR in the next 12 months and beyond. we have appointed ground company representatives in France and India and in the process of adding UK, Germany, Spain and France. started individual country trials in France and India with the others to follow.

we are engaging cassette and kit assembly in Europe, Mid-Asia, Australia and North America. Derek even highlighted today that this could happen in areas where it is cheaper to do than in Europe and Australia. (india???)

we are working on different readers for different markets. discussions have already started to happen with larger companies to work together (todays interview) I haven't forgot about the potential to licence our tests.

the funding has also allowed us to fast track all our work on the battery side of the business eg commercialisation of AnteoX

even Derek today claimed as a proxy of our ambition in the market, we look to Quidel and Abbot. years ago both were in a similar position to us. Quidel revenue 2020 $1.6B, Abbot revenue 2020 $34.6B. it seems that Derek's mantra to understate is loosening.


so all of this involves many ifs and maybes, but covid has enabled Anteotech to grow exponentially. it's just over a year ago we announced proof of concept of our sepsis test. look how far we have come!!! and it's all because of our special glue. allowed us to create a top5 covid nasal swab test, a exceptionally sensitive covid saliva test and a quantitative multiplex sepsis test, so far. all my research shows that our EuGeni platform is gold standard.

IMO, we will get many orders and we will have large corporation wanting to partner with us. how big we will get, who knows but I am sure glad I have loaded up my portfolio with anteotech while I am waiting for those checks to come. DYOR, IMO, etc

and thats all I have to say about that....











ps. another reason I posted this was to get the naysayers all stirred up.